Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
295M
-
Number of holders
-
118
-
Total 13F shares, excl. options
-
52.6M
-
Shares change
-
-9.01M
-
Total reported value, excl. options
-
$34.5M
-
Value change
-
-$6.97M
-
Put/Call ratio
-
0.83
-
Number of buys
-
53
-
Number of sells
-
-60
-
Price
-
$0.66
Significant Holders of SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) as of Q1 2025
157 filings reported holding SGMO - SANGAMO THERAPEUTICS, INC - Common Stock as of Q1 2025.
SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) has 118 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 52.6M shares
of 295M outstanding shares and own 17.84% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (9.37M shares), WASATCH ADVISORS LP (6.87M shares), BlackRock, Inc. (5.45M shares), RENAISSANCE TECHNOLOGIES LLC (3.17M shares), GEODE CAPITAL MANAGEMENT, LLC (2.28M shares), Point72 Asset Management, L.P. (2M shares), Ikarian Capital, LLC (1.86M shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (1.81M shares), JACOBS LEVY EQUITY MANAGEMENT, INC (1.3M shares), and MILLENNIUM MANAGEMENT LLC (1.17M shares).
This table shows the top 118 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.